Shots:

• Immunocore to receive $100M upfront plus milestone payment and has an option to license IMC-C103C or grant its full rights to Genentech. If not exercised option to license- Immunocore will receive milestones and royalties
• Immunocore will conduct clinical trial to evaluate IMC-C103C as a monothx or in combination with Tecentriq (atezolizumab)- which will be initiated in H1’19
• IMC-C103C is a mAb- is being developed for targeting tumors expressing protein MAGE-A4 (Melanoma-Associated Antigen A4)

Ref: Immunocore| Image: Center for Health Journalism